|
1
|
Derosa G: Efficacy and tolerability of
pioglitazone in patients with type 2 diabetes mellitus: Comparison
with other oral antihyperglycaemic agents. Drugs. 70:1945–1961.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McDonough AK, Rosenthal RS, Cao X and Saag
KG: The effect of thiazolidinediones on BMD and osteoporosis. Nat
Clin Pract Endocrinol Metab. 4:507–513. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Montagnani A and Gonnelli S: Antidiabetic
therapy effects on bone metabolism and fracture risk. Diabetes Obes
Metab. 15:784–791. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Raggatt LJ and Partridge NC: Cellular and
molecular mechanisms of bone remodeling. J Biol Chem.
285:25103–25108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lazner F, Gowen M, Pavasovic D and Kola I:
Osteopetrosis and osteoporosis: Two sides of the same coin. Hum Mol
Genet. 8:1839–1846. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khosla S: Minireview: The OPG/RANKL/RANK
system. Endocrinology. 142:5050–5055. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eriksen EF: Cellular mechanisms of bone
remodeling. Rev Endocr Metab Disord. 11:219–227. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lehmann JM, Moore LB, Smith-Oliver TA,
Wilkison WO, Willson TM and Kliewer SA: An antidiabetic
thiazolidinedione is a high affinity ligand for peroxisome
proliferator-activated receptor gamma (PPAR gamma). J Biol Chem.
270:12953–12956. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tontonoz P, Hu E and Spiegelman BM:
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a
lipid-activated transcription factor. Cell. 79:1147–1156. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
MacDougald OA and Lane MD: Transcriptional
regulation of gene expression during adipocyte differentiation.
Annu Rev Biochem. 64:345–373. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gimble JM, Robinson CE, Wu X, Kelly KA,
Rodriguez BR, Kliewer SA, Lehmann JM and Morris DC: Peroxisome
proliferator-activated receptor-gamma activation by
thiazolidinediones induces adipogenesis in bone marrow stromal
cells. Mol Pharmacol. 50:1087–1094. 1996.PubMed/NCBI
|
|
12
|
Mabilleau G, Chappard D and Baslé MF:
Cellular and molecular effects of thiazolidinediones on bone cells:
A review. Int J Biochem Mol Biol. 2:240–246. 2011.PubMed/NCBI
|
|
13
|
Wang L, Li L, Gao H and Li Y: Effect of
pioglitazone on transdifferentiation of preosteoblasts from rat
bone mesenchymal stem cells into adipocytes. J Huazhong Univ Sci
Technolog Med Sci. 32:530–533. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu L, Aronson J and Lecka-Czernik B:
Rosiglitazone disrupts endosteal bone formation during distraction
osteogenesis by local adipocytic infiltration. Bone. 52:247–258.
2013. View Article : Google Scholar
|
|
15
|
Cho ES, Kim MK, Son YO, Lee KS, Park SM
and Lee JC: The effects of rosiglitazone on osteoblastic
differentiation, osteoclast formation and bone resorption. Mol
Cells. 33:173–181. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Viccica G, Francucci CM and Marcocci C:
The role of PPARγ for the osteoblastic differentiation. J
Endocrinol Invest. 33(Suppl 7): S9–S12. 2010.
|
|
17
|
Yamashita A, Takada T, Nemoto K, Yamamoto
G and Torii R: Transient suppression of PPARgamma directed ES cells
into an osteoblastic lineage. FEBS Lett. 580:4121–4125. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jeon MJ, Kim JA, Kwon SH, Kim SW, Park KS,
Park SW, Kim SY and Shin CS: Activation of peroxisome
proliferator-activated receptor-gamma inhibits the Runx2-mediated
transcription of osteocalcin in osteoblasts. J Biol Chem.
278:23270–23277. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bruedigam C, Eijken M, Koedam M, van de
Peppel J, Drabek K, Chiba H and van Leeuwen JP: A new concept
underlying stem cell lineage skewing that explains the detrimental
effects of thiazolidinediones on bone. Stem Cells. 28:916–927.
2010.PubMed/NCBI
|
|
20
|
Teitelbaum SL and Ross FP: Genetic
regulation of osteoclast development and function. Nat Rev Genet.
4:638–649. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chan BY, Gartland A, Wilson PJ, Buckley
KA, Dillon JP, Fraser WD and Gallagher JA: PPAR agonists modulate
human osteoclast formation and activity in vitro. Bone. 40:149–159.
2007. View Article : Google Scholar
|
|
22
|
Wan Y, Chong LW and Evans RM: PPAR-gamma
regulates osteoclastogenesis in mice. Nat Med. 13:1496–1503. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu H, Li L, Ma Y, Chen Y, Zhao J, Lu Y and
Shen P: Regulation of selective PPARγ modulators in the
differentiation of osteoclasts. J Cell Biochem. 114:1969–1977.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wei W, Wang X, Yang M, Smith LC, Dechow
PC, Sonoda J, Evans RM and Wan Y: PGC1beta mediates PPARgamma
activation of osteoclastogenesis and rosiglitazone-induced bone
loss. Cell Metab. 11:503–516. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hofbauer LC, Khosla S, Dunstan CR, Lacey
DL, Boyle WJ and Riggs BL: The roles of osteoprotegerin and
osteoprotegerin ligand in the paracrine regulation of bone
resorption. J Bone Miner Res. 15:2–12. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Muruganandan S, Roman AA and Sinal CJ:
Adipocyte differentiation of bone marrow-derived mesenchymal stem
cells: Cross talk with the osteoblastogenic program. Cell Mol Life
Sci. 66:236–253. 2009. View Article : Google Scholar
|
|
27
|
Lazarenko OP, Rzonca SO, Hogue WR, Swain
FL, Suva LJ and Lecka-Czernik B: Rosiglitazone induces decreases in
bone mass and strength that are reminiscent of aged bone.
Endocrinology. 148:2669–2680. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park JS, Cho MH, Nam JS, Yoo JS, Ahn CW,
Cha BS, Kim KR and Lee HC: Effect of pioglitazone on serum
concentrations of osteoprotegerin in patients with type 2 diabetes
mellitus. Eur J Endocrinol. 164:69–74. 2011. View Article : Google Scholar
|
|
29
|
Sultan A, Avignon A, Galtier F, Piot C,
Mariano-Goulart D, Dupuy AM and Cristol JP: Osteoprotegerin,
thiazolidinediones treatment and silent myocardial ischemia in type
2 diabetic patients. Diabetes Care. 31:593–595. 2008. View Article : Google Scholar
|
|
30
|
Krause U, Harris S, Green A, Ylostalo J,
Zeitouni S, Lee N and Gregory CA: Pharmaceutical modulation of
canonical Wnt signaling in multipotent stromal cells for improved
osteoinductive therapy. Proc Natl Acad Sci USA. 107:4147–4152.
2010. View Article : Google Scholar : PubMed/NCBI
|
